Pharma BD Deal Intelligence
Mylan's $6.7B all-cash acquisition of Merck Generics roughly doubled its revenue overnight and made it the third-largest generics player globally, with the Dey/EpiPen franchise growing from ~$200M to ~$1B by 2015. Though EpiPen's price hikes later triggered a congressional hearing and a $465M DOJ settlement, and a Dey specialty unit took a $385M writedown within months of close.
Transformative scale-up that made Mylan a top-tier global generics player and delivered EpiPen as an unplanned blockbuster, but that same asset later triggered a pricing scandal, and one acquired unit (Dey/Perforomist) was written down within months of close.
Full analysis, sources & comparables →Mylan's $6.7B acquisition of Merck Generics was viewed as transformative — moving Mylan from #3 US generics player to a top-tier global specialty/generics…
EpiPen — acquired in the Merck KGaA deal — held ~90% US autoinjector share at ~$200M annual sales in 2007; Mylan grew it past $1B by 2014, eventually drawing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 4.9B / $6.7B cash. EpiPen included. Closed Oct 2, 2007. Source: Mylan investor release, FTC, Business Standard.
Transformative scale-up that made Mylan a top-tier global generics player and delivered EpiPen as an unplanned blockbuster, but that same asset later triggered a pricing scandal, and one acquired unit (Dey/Perforomist) was written down within months of close.
Assessment window: 15yr post-close.
$200M EpiPen US sales ~$200M at deal time (2007)
The Mylan-Merck Generics deal is a generics platform transaction with one strategic specialty asset: EpiPen, the dominant epinephrine autoinjector for life-threatening anaphylaxis. Anaphylaxis is a rapid-onset, IgE-mediated systemic allergic reaction triggered by foods, insect venoms, drugs, and latex — untreated it causes airway closure and shock. EpiPen delivers 0.3 mg (adult) or 0.15 mg (pediatric) intramuscular epinephrine via a spring-loaded autoinjector.
On the generics side, Merck KGaA's generics arm carried roughly 560 marketed products and held leadership positions in Australia, France, Japan, Portugal, Spain, and the UK (PharmaTimes, https://pharmatimes.com/news/mylan_wins_battle_to_acquire_merck_kgaas_generics_unit_989862/). Combined 2006 pro-forma revenues approached $4.2B. The deal vaulted Mylan from third-largest US generics player to second-largest global generics company, behind Teva (post-IVAX) and ahead of Novartis-Sandoz on a pure generics basis. Teva, the initial favored bidder, withdrew over financial-criteria concerns; Actavis also dropped out late, leaving Mylan as the winner at the upper analyst valuation range. On the specialty side, EpiPen brought roughly $200M in sales and ~90% market share of the US epinephrine autoinjector category at deal close. Direct competitors included Sciele Pharma's Twinject and later Adamis/Impax/Adrenaclick variants, none of which displaced EpiPen's pharmacy formulary lock. Mylan went on to grow EpiPen revenue to over $1B by 2014 through aggressive list-price increases and school-stocking laws — actions that triggered Congressional scrutiny in 2016. Strategically the deal repositioned Mylan from US-centric ANDA filer to multinational generics-and-specialty platform, bridging it to its 2015 Meda acquisition and 2020 Pfizer Upjohn merger forming Viatris.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) (this deal) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2005 | $736M | 39 |
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. | 2004 | $4.0B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |